Recent news on Sodium Phenylbutyrate

Medicis Begins Shipping PERLANE to Physicians  -  May 21, 2007
Primenewswire (press release),...and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium

Access Pharmaceuticals Signs Definitive Merger Agreement With ...  -  Apr 19, 2007
Earthtimes.orgSomanta's lead clinical product Sodium Phenylbutyrate (PB) is currently in Phase 2 development and is being developed with its partner,

Medicis Declares Cash Dividend  -  Mar 14, 2007
Primenewswire (press release),...and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium

Medicis Announces 2006 Fourth Quarter and Year-End Conference Call ...  -  Feb 26, 2007
Primenewswire (press release),BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea

Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta ...  -  Feb 26, 2007
Drug Newswire (press release),Somanta's lead clinical product Sodium Phenylbutyrate (PB) is currently in Phase 2 development. In National Institute of Health sponsored trials,

Access Pharmaceuticals Hones in on Oncology Focus with Acquisition  -  Feb 21, 2007
Genetic Engineering News (press release),Somanta's Phase II product, sodium phenylbutyrate (PB), is being evaluated for recurrent glioblastoma and prostate cancer.

Medicis to Present At Roth Capital Partners 19th Annual OC Conference  -  Feb 15, 2007
PharmaLive.com (press release),BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea

Access Pharmaceuticals Signs Letter Of Intent To Acquire Somanta ...  -  Feb 22, 2007
PipelineReview.com (press release),Somanta's lead clinical product Sodium Phenylbutyrate (PB) is currently in Phase 2 development. In National Institute of Health sponsored trials,

Somanta Announces Data to Be Presented on Angiolix for Targeting ...  -  Feb 1, 2007
PharmaLive.com (press release),Somanta's lead clinical product is Sodium Phenylbutyrate (PB), for which it is scheduling and planning a Phase IIb clinical trial involving a central

Medicis to Present At JPMorgan 25th Annual Healthcare Conference  -  Jan 4, 2007
PharmaLive.com (press release),BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea

Somanta Signs Letter of Intent to Expand Sublicense Agreement with ...  -  Dec 13, 2006
PharmaLive.com (press release),Sodium Phenylbutyrate (PB) is a safe, well-tolerated compound that has been used in a pediatric indication, hyperuremia, for many years.

Medicis Declares Cash Dividend  -  Dec 14, 2006
Primenewswire (press release),BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional